longtermgevity

To develop transformative biotechnologies that provide sustained relief from chronic conditions and solve the fundamental challenges of aging through innovation

[longtermgevity @longtermgevity]

Call for Participants!

The Sensorimotor Exploration Lab of Queen's University, in partnership with LongTermGevity Inc., is thrilled to announce its first-ever study on Psilocybin and Motor Perception. We are currently seeking participants who meet the research criteria

[longtermgevity @longtermgevity]

https://t.co/If78FxaFNQ

[Microdose Psychedelic Insights @MicrodoseHQ]

Colorado just legalized ‘magic mushrooms,’ an idea that’s growing nationwide. The state is the second to approve regulated use amid a growing body of research into psilocybin’s therapeutic uses.

- From @NBCNews

#psychedelic #psychedelic #MentalHealth
https://t.co/MguRu9LyHy

[longtermgevity @longtermgevity]

@longtermgevity and TheraPsil will be in Ottawa next week to meet with MPs and lobby for medical psilocybin regulations for Canadians.

[longtermgevity @longtermgevity]

LongTermGevity has long believed that psilocybin has many benefits to humanity. Not only in mental health but also physical health. We aim to bring this medicine to the market by conducting research along with Queens University. https://t.co/vzA5tRIKhv

[Microdose Psychedelic Insights @MicrodoseHQ]

John Hopkins Study Finds #Psilocybin 4x More Effective Than Antidepressants 🍄🍄
https://t.co/RNtXoBby7n

[longtermgevity @longtermgevity]

Also, our Clinical Advisory Team has extensive experience running trials in spinal cord stimulation, mental health disorders and neurological diseases and injuries. To learn more about our team highlights, visit https://t.co/vdWD5zt6hU

[longtermgevity @longtermgevity]

At LTG, we have some of the best minds behind us -- our Science Team has vast pharmaceutical experience having held senior positions at Dr. Reddy’s Laboratories and Novo Nordisk, facilitating numerous clinical trials and launching drugs to market.

[longtermgevity @longtermgevity]

"Health is a state of complete harmony of the body, mind and spirit. When one is free from physical disabilities and mental distractions, the gates of the soul open."

[longtermgevity @longtermgevity]

...should be made available to patients with treatment-resistant anxiety, depression, or PTSD.
To learn more, read the full Forbes article here: https://t.co/neJ4vZyqNE

[longtermgevity @longtermgevity]

A new study found that 65% of affected Americans want access to psychedelics for mental health. Respondents who self-reported that they suffer from a mental health condition say that psychedelic medicine including ketamine, psilocybin mushrooms, and MDMA... (1/2)

[longtermgevity @longtermgevity]

The study, published in The Journal of Psychopharmacology, has been described as "an essential first step in demonstrating the safety and feasibility" in the therapeutic uses of the drug – which is currently prohibited in the UK as a Class A substance.

[longtermgevity @longtermgevity]

Renewed scientific interest in psychedelics as a treatment for depression, anxiety, and even substance abuse has led to a fresh wave of mind-expanding medical findings.
https://t.co/4K9sgxbViS

[longtermgevity @longtermgevity]

Psilocybin, the psychedelic compound produced by more than 200 species of fungi – often known as 'magic mushrooms' – can be safely given to patients to treat a range of mental health conditions, according to groundbreaking new research by King's College London.

[longtermgevity @longtermgevity]

"Imagination belongs to hope. It’s the creative dance of possibility." - Sharon Weil

#LongTermGevity #MentalHealthTherapeutics #psychedelicMedicine #psychedelicTherapy #psychedelicWellness #Psilocybin #MentalHealthMatters #MentalHealthAdvocates

[longtermgevity @longtermgevity]

We aim to become the first life sciences company to bring a psilocybin drug to market targeting improved motor function for patients with depression. To learn more about our clinical trials: https://t.co/yR0SXvVCqR

#LongTermGevity #MentalHealthTherapeutics #PsilocybinResearch

[longtermgevity @longtermgevity]

Psychedelic microdosing has increased as a coping tool for mental health concerns during the COVID-19 pandemic, according to the 2021 Global Drug Survey. To read the full article, visit: https://t.co/f3vt9Z48GI

[longtermgevity @longtermgevity]

A November 2021 study by the University of British Columbia (UBC), observed that people who microdosed psychedelics, such as #psilocybin and LSD, reported less anxiety, depression, and stress than non-microdosers.

[longtermgevity @longtermgevity]

(source: https://t.co/tmX8KkGQDt)

#LongTermGevity #MentalHealthTherapeutics #psychedelicMedicine #psychedelicTherapy #psychedelicWellness #Psilocybin #PsilocybinResearch #MentalHealthMatters #MentalHealthAdvocates #Depression

[longtermgevity @longtermgevity]

1 in 5 (21%) Canadians screened positive for depression, anxiety or post-traumatic stress disorder, as per a new Survey on COVID-19 and Mental Health, funded and developed by the Public Health Agency of Canada (PHAC), in collaboration with Statistics Canada.

[longtermgevity @longtermgevity]

At LTG, we have a Phase 1 clinical trial at Queen's University with the objective of exploring the effects of psilocybin on the sensory perception for those patients with and without depression. To learn more about our clinical trials, visit https://t.co/VRVk82Eqss